Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
New AHA/ASA guidelines recommend stent retrievers to treat strokes in selected patients

New AHA/ASA guidelines recommend stent retrievers to treat strokes in selected patients

New devices called stent retrievers are enabling physicians to benefit selected patients who suffer strokes caused by blood clots. The devices effectively stop strokes in their tracks. [More]
Study: Genes may not trigger heart disease in people suffering from migraine with aura

Study: Genes may not trigger heart disease in people suffering from migraine with aura

A new study suggests that genes may not be to blame for the increased risk of heart disease some studies have shown in people with migraine, especially those with migraine with aura. The research is published during Headache/Migraine Awareness Month in the inaugural issue of the journal Neurology Genetics, an open access, or free to the public, online-only, peer-reviewed journal from the American Academy of Neurology. [More]
Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. [More]
Study demonstrates the important role of placebo effect in medical care

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients. [More]
Two migraine surgery techniques equally effective in reducing severity of migraine headaches

Two migraine surgery techniques equally effective in reducing severity of migraine headaches

Two migraine surgery techniques targeting a specific "trigger site" are both highly effective in reducing the frequency and severity of migraine headaches, according to a randomized trial in the July issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons. [More]
Athletes need to drink when thirsty to avoid exercise-associated hyponatremia

Athletes need to drink when thirsty to avoid exercise-associated hyponatremia

For hikers, football players, endurance athletes, and a growing range of elite and recreational exercisers, the best approach to preventing potentially serious reductions in blood sodium level is to drink when thirsty, according to an updated consensus statement on exercise-associated hyponatremia (EAH). [More]
Symptoms and characteristics of cluster headache

Symptoms and characteristics of cluster headache

June is National Migraine and Headache Awareness Month. The global burden of headache is extremely large, putting headache among the top 10 causes of disability worldwide. [More]
Rising number of malaria deaths likely to exceed total number of Ebola deaths

Rising number of malaria deaths likely to exceed total number of Ebola deaths

Around 74000 fewer malaria cases than expected were seen at health facilities in Guinea in 2014 compared with pre-Ebola years, new research published in The Lancet Infectious Diseases journal has found. [More]
GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GlaxoSmithKline announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). [More]
CSL Behring presents Phase I/III rVIII-SingleChain hemophilia A data at 2015 ISTH Congress

CSL Behring presents Phase I/III rVIII-SingleChain hemophilia A data at 2015 ISTH Congress

CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress. [More]

KeyLemon, onefacein team up to provide affordable and effective biometric solutions

Biometry authentication provider KeyLemon today announced a strategic partnership with emerging biometric password solution onefacein. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine. [More]
Effective medical communication missing between physicians and patients with chronic migraine

Effective medical communication missing between physicians and patients with chronic migraine

Many patients with chronic migraine (CM) receive suboptimal medical treatment even when they seek medical care. Reporting at the annual scientific meeting of the American Headache Society, researchers found that the majority of clinical encounters between CM patients and physicians were missing essential components of effective communication. [More]
CGRP monoclonal antibodies show promise in treating migraine

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine. [More]
Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Designing infectious disease forecasting models to predict dengue epidemics

Designing infectious disease forecasting models to predict dengue epidemics

Dengue viruses are on the move. Spread among humans by mosquitoes, and across geographic boundaries through travel, the virus affects up to an estimated 390 million people every year around the world. In the U.S., recent outbreaks have occurred in Florida, Texas, Hawaii, and Puerto Rico. Scientists know one of the best ways to reduce the impact of the disease is to prepare healthcare providers by forecasting epidemics before they happen. [More]
GBD analysis shows over 95% of global population has health problems

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet. [More]
FDA grants exclusivity to Flublok influenza vaccine for 12 years

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine. [More]
Advertisement